CIBC Asset Management
CORT icon

CIBC Asset Management’s Corcept Therapeutics CORT Stock Holding History

CIBC Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
+3,290
New +$199K ﹤0.01% 1081
2025
Q4 		– Sell
-3,340
Closed -$278K – 1377
2025
Q3 		$278K Hold
3,340
– – ﹤0.01% 966
2025
Q2 		$245K Hold
3,340
– – ﹤0.01% 987
2025
Q1 		$381K Buy
+3,340
New +$203K ﹤0.01% 793
2024
Q4 		– Sell
-5,214
Closed -$241K – 1235
2024
Q3 		$241K Buy
+5,214
New +$185K ﹤0.01% 986

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Asset Management's CORT Position: Q2 2026 in Review

CIBC Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,290 shares worth $286K. The stake represents ﹤0.01% of the portfolio and ranks #1081 among its holdings. This is a return to the name: CIBC Asset Management previously reported a position in CORT as recently as Q3 2025.

CIBC Asset Management first reported a position in CORT in Q3 2024 and has held it in 5 quarters since. The position peaked at $381K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • CIBC Asset Management held 3,290 shares of Corcept Therapeutics worth $286K as of Q2 2026.
  • Corcept Therapeutics was a new CIBC Asset Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1081 holding.
  • CIBC Asset Management first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • CIBC Asset Management's Corcept Therapeutics position peaked at $381K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.